16 January 2020 - Deborah Wilkes
Beiersdorf and artificial intelligence company Insilico Medicine are working together on computer-simulated skin research.
The German skincare specialist said the aim was to discover “novel and safe bioactive ingredients for a specific skin indication”.
May Shana’a – Beiersdorf’s senior corporate vice president for research and development – said the collaboration would allow new active ingredients to be evaluated “more quickly and more efficiently by simulating biological effects in silico”.
Alex Zhavoronkov, chief executive officer of Insilico Medicine, said Beiersdorf had become an “undisputed leader in the area of skin research as well as in digital technologies in recent decades”.
“We are delighted that they have recognised the potential of artificial intelligence early on,” added Zhavoronkov, “and hope to demonstrate the power of artificial intelligence going forward in our collaboration.”
Insilico Medicine aims to be “a leader in the field of deep learning for drug discovery, personalised healthcare, and anti-ageing interventions”.
Beiersdorf said it was a leader in the development and application of novel artificial intelligence technologies to skincare and was collaborating with an ecosystem of startup companies.
Beiersdorf has just released its 2019 financial results. The company's Consumer division reported worldwide sales up by 4.8% on an organic basis to EUR6.27 billion (USD6.95 billion), with the Nivea, Eucerin, Aquaphor and La Prairie brands all contributing to growth (click here to read the News story)